Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors.
Sanz-Gómez M, Manzano-Lista FJ, Vega-Martín E, González-Moreno D, Alcalá M, Gil-Ortega M, Somoza B, Pizzamiglio C, Ruilope LM, Aránguez I, Kolkhof P, Kreutz R, Fernández-Alfonso MS. Sanz-Gómez M, et al. Among authors: kolkhof p. Biomed Pharmacother. 2023 Dec;168:115661. doi: 10.1016/j.biopha.2023.115661. Epub 2023 Oct 11. Biomed Pharmacother. 2023. PMID: 37832406 Free article.
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL. Agarwal R, et al. Among authors: kolkhof p. J Hypertens. 2023 Feb 1;41(2):295-302. doi: 10.1097/HJH.0000000000003330. Epub 2022 Dec 8. J Hypertens. 2023. PMID: 36583355 Free PMC article. Clinical Trial.
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
Perakakis N, Bornstein SR, Birkenfeld AL, Linkermann A, Demir M, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Kolkhof P, Lawatscheck R, Scott C, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Perakakis N, et al. Among authors: kolkhof p. Diabetes Obes Metab. 2024 Jan;26(1):191-200. doi: 10.1111/dom.15305. Epub 2023 Oct 10. Diabetes Obes Metab. 2024. PMID: 37814928
Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists.
Abedini A, Sánchez-Navaro A, Wu J, Klötzer KA, Ma Z, Poudel B, Doke T, Balzer MS, Frederick J, Cernecka H, Liu H, Liang X, Vitale S, Kolkhof P, Susztak K. Abedini A, et al. Among authors: kolkhof p. J Clin Invest. 2024 Jan 2;134(1):e157165. doi: 10.1172/JCI157165. J Clin Invest. 2024. PMID: 37906287 Free PMC article.
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, Groop PH, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Scott C, Edfors R, Scheerer MF, Kolkhof P, McGill JB. Heerspink HJL, et al. Among authors: kolkhof p. Diabetes Res Clin Pract. 2023 Oct;204:110908. doi: 10.1016/j.diabres.2023.110908. Epub 2023 Oct 5. Diabetes Res Clin Pract. 2023. PMID: 37805000 Free article. Clinical Trial.
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
Koya D, Anker SD, Ruilope LM, Rossing P, Liu Z, Lee BW, Lee CT, Scott C, Kolkhof P, Lawatscheck R, Wang L, Joseph A, Pitt B; FIDELIO-DKD Investigators. Koya D, et al. Among authors: kolkhof p. Am J Nephrol. 2023;54(9-10):370-378. doi: 10.1159/000532102. Epub 2023 Sep 14. Am J Nephrol. 2023. PMID: 37708857 Free article. Clinical Trial.
109 results